Adaptive Biotechnologies Corp (NASDAQ: ADPT) is a biotechnology company that uses its immune medicine platform to decode the adaptive immune system for disease detection and treatment applications. Revenue comes from two reported segments: MRD (minimal residual disease) testing for blood cancers and immune medicine research services. The MRD segment generates clinical testing revenue by processing patient samples through its clonoSEQ assay, an FDA-cleared test used to monitor certain blood cancers. The immune medicine segment has historically included collaboration revenue, most notably from a now-terminated agreement with Genentech. Adaptive was founded in 2009 and is headquartered in Seattle, Washington. The filing covering fiscal year ended December 31, 2025 references restructuring activity, impairment of long-lived assets, and an adjusted EBITDA non-GAAP metric, indicating the company has not reached GAAP profitability. The termination of the Genentech agreement is disclosed as a material event affecting the composition of revenue going forward.

Revenue model

Clinical testing fees from the clonoSEQ MRD assay and collaboration or research services revenue from immune medicine partnerships, including a now-terminated Genentech agreement, as reported in the 10-K filed 2026-02-26 for FY2025.

Products and services

clonoSEQ assay (FDA-cleared minimal residual disease test for blood cancers); immune medicine research and collaboration services.

Customers and end markets

Oncology clinicians and hospitals ordering MRD testing for blood cancer patients; biopharmaceutical partners for immune medicine research collaborations.

Value-chain role

Diagnostic testing laboratory and immunology data platform; sits between patient sample collection and clinical decision-making for blood cancer monitoring.

Geographic exposure

Filing does not provide a breakdown of geographic revenue in the excerpts provided.

Source: SEC 10-K, filed 2026-02-26

Industry: Biological Products, (No Diagnostic Substances) Peers: 10X Genomics Inc Neogenomics Inc Bionano Genomics Inc SomaLogic, Inc. Cytek Biosciences Inc MaxCyte Inc Pacific Biosciences of California Inc NS Wind Down Co., Inc. Sotera Health Co Thermo Fisher Scientific Inc